PHILADELPHIA, Nov. 06, 2025 (GLOBE NEWSWIRE) --
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) - Class Action Survives Motion to Dismiss:
Grabar Law Office is investigating claims on behalf of shareholders of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) as securities fraud class action complaint allegations have survived a motion to dismiss.
If you purchased Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) prior to May 11, 2023, and still hold shares today, you can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever.
Please visit https://grabarlaw.com/the-latest/amylyx-shareholder-investigation/, contact Joshua Grabar at jgrabar@grabarlaw.com, or call 267-507-6085.
WHY? Key allegations of a recently filed securities fraud class action complaint filed against Amylyx Pharmaceuticals, Inc., (NASDAQ: AMLX) and certain of its officers, have now survived Defendants’ motion to dismiss that complaint. The underlying securities fraud class action complaint alleges that, Amylyx Pharmaceuticals, Inc., through certain of its officers and directors, made materially false and misleading statements regarding the Company’s business, operations, and prospects in that: (i) Defendants had overstated Relyvrio’s commercial prospects; (ii) patients were discontinuing treatment with Relyvrio after six months; (iii) the rate at which new patients were starting treatment with Relyvrio was decreasing; (iv) accordingly, Defendants had also overstated Relyvrio’s prescription rate; (v) Defendants attempted to hide the foregoing negative trends from investors and the market by blocking analysts from viewing Relyvrio’s prescription data; and (vi) as a result, Defendants’ public statements were materially false and misleading at all relevant times. Then on April 4, 2024, Amylyx announced it was pulling Relyvrio from the market.
WHAT YOU CAN DO NOW: If you purchased Amylyx Pharmaceuticals, Inc., (NASDAQ: AMLX) prior to May 11, 2023, and still hold shares today, you are encouraged to visit https://grabarlaw.com/the-latest/amylyx-shareholder-investigation/, contact Joshua Grabar at jgrabar@grabarlaw.com, or call 267-507-6085. You can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever. $AMLX #Amylyx #AMLX
Avantor, Inc. (NYSE: AVTR):
Grabar Law Office is investigating claims on behalf of shareholders of Avantor, Inc. (NYSE: AVTR). The investigation concerns whether certain officers and directors breached the fiduciary duties they owed to the company.
If you purchased Avantor, Inc. (NYSE: AVTR), shares prior to March 5, 2024 and still hold shares today, you can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever. Please visit https://grabarlaw.com/the-latest/avantor-shareholder-investigation/, contact Joshua Grabar at jgrabar@grabarlaw.com, or call 267-507-6085 to learn more.
WHY? As alleged in a recently filed underlying securities fraud class action complaint, Avantor, Inc. (NYSE: AVTR), through certain of its officers, made materially false and misleading statements materially false and/or misleading statements, as well as failed to disclose material adverse facts, about the Company’s business and operations. Specifically, Defendants misrepresented and/or failed to disclose that: (1) Avantor’s competitive positioning was weaker than Defendants had publicly represented; (2) Avantor was experiencing negative effects from increased competition; and (3) as a result, Defendants’ representations about the Company’s business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis.
WHAT YOU CAN DO NOW: If you purchased Avantor, Inc. (NYSE: AVTR), shares prior to March 5, 2024 and still hold shares today, you are encouraged to visit https://grabarlaw.com/the-latest/avantor-shareholder-investigation/, contact Joshua Grabar at jgrabar@grabarlaw.com, or call 267-507-6085. You can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever. $AVTR #Avantor
Humana Inc. (NYSE: HUM):
Grabar Law Office is investigating claims on behalf of shareholders of Humana Inc. (NYSE: HUM). The investigation concerns whether certain officers and directors breached the fiduciary duties they owed to the company.
If you purchased Humana Inc. (NYSE: HUM), shares prior to July 27, 2022, and still hold shares today, you can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever.
Please visit https://grabarlaw.com/the-latest/humana-shareholder-investigation/, contact Joshua Grabar at jgrabar@grabarlaw.com, or call 267-507-6085 to learn more.
WHY? As alleged in a recently filed federal securities fraud class action complaint, Humana Inc. (NYSE: HUM), through certain of its officers, made materially false and/or misleading statements, as well as failed to disclose material adverse facts, about the Company’s business and operations. Specifically, the Complaint alleges Defendants downplayed pressures on the Company’s adjusted EPS resulting from increased medical costs associated with pent-up demand for healthcare procedures (especially as COVID concerns abated) which, contrary to the Company’s assurances, resulted in increased utilization rates and costs.
WHAT YOU CAN DO NOW: If you purchased Humana Inc. (NYSE: HUM), shares prior to July 27, 2022, and still hold shares today, you are encouraged to visit https://grabarlaw.com/the-latest/humana-shareholder-investigation/, contact Joshua Grabar at jgrabar@grabarlaw.com, or call 267-507-6085. You can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever. #HUM $HUM #Humana
Maison Solutions Inc. (NASDAQ: MSS) - Securities Fraud Class Action Survives Motion to Dismiss and is Now Stayed Pending Attempts to Settle:
Grabar Law Office is investigating claims on behalf of shareholders of Maison Solutions Inc. (NASDAQ: MSS) as an underlying securities fraud class action has survived a motion to dismiss the complaint and is now stayed pending attempts to settle the case. The investigation concerns whether certain officers and directors breached the fiduciary duties they owed to the company.
If you are a current Maison Solutions Inc. (NASDAQ: MSS) shareholder who purchased Maison shares on or shortly after its October 5, 2023 IPO and still hold shares today, you may be able to seek corporate reforms, the return of money back to the company, and a court approved incentive award at no cost to you whatsoever. Please visit https://grabarlaw.com/the-latest/maison-shareholder-investigation/, contact Joshua Grabar at jgrabar@grabarlaw.com or call us at 267-507-6085
WHY?: Key allegations in an underlying securities fraud class action complaint against Maison Solutions Inc. (NASDAQ: MSS) have survived a motion to dismiss and the case is stayed pending settlement of the matter. The complaint alleges that in the Registration Statement and throughout the Class Period (October 5, 2023 through December 15, 2023), Maison, through certain of its officers, made materially false and/or misleading statements, including failing to disclose to investors: (1) that the Company’s vendor XHJC Holdings Inc., is a related party; (2) that the Company’s CEO and related entities were alleged to have used supermarkets as a front to defraud the EB-5 visa program; and (3) that, as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
On March 31, 2025, material portions of the underlying complaint survived a motion to dismiss.
On October 28, 2025, the court Ordered a stay in the class action litigation pending the parties attempts to reach settlement.
WHAT YOU CAN DO NOW: If you purchased Maison Solutions Inc. (NASDAQ: MSS) on or shortly after its October 5, 2023 IPO and still hold shares today, you are encouraged visit https://grabarlaw.com/the-latest/maison-shareholder-investigation/, contact Joshua Grabar at jgrabar@grabarlaw.com, or call 267-507-6085. You can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever. #Maison $MSS
Attorney Advertising Disclaimer
Contact:
Joshua H. Grabar, Esq.
Grabar Law Office
One Liberty Place
1650 Market Street, Suite 3600
Philadelphia, PA 19103
Tel: 267-507-6085
Email: jgrabar@grabarlaw.com
